- Update: FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer.
- [No author given]
- FORCE. 2020 Jul 7.
- News
- Free Full Text
Original research:
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
- PMID: 31851799
- PubMed abstract
- Source abstract
- Lifestyle Choices May Reduce Breast Cancer Risk Regardless of Genetics.
- Otto MA.
- Medscape. 2020 Jul 7.
- Research news
- Free Full Text
Original research:
Association of Nongenetic Factors With Breast Cancer Risk in Genetically Predisposed Groups of Women in the UK Biobank Cohort.
- PMID: 32329772
- PubMed abstract
- Free Full Text
Research news: Lifestyle choices may reduce breast cancer risk regardless of genetics. (MDedge | Hematology & Oncology)
- Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier.
- Desai NV, Tung NM.
- Breast J. 2020 Jul 6. doi: 10.1111/tbj.13972. Online ahead of print.
- Review
- Complex Characterization of Germline Large Genomic Rearrangements of the BRCA1 and BRCA2 Genes in High-Risk Breast Cancer Patients-Novel Variants from a Large National Center.
- Bozsik A, Pócza T, Papp J, Vaszkó T, Butz H, Patócs A, Oláh E.
- Int J Mol Sci. 2020 Jun 30;21(13):E4650. doi: 10.3390/ijms21134650.
- PMID: 32629901
- PubMed abstract
- Source abstract
- Small Steps in Pancreatic Cancer – Episode 2: Relatives at Risk.
- McAllister F, Maitra A, Burton M, McGuire M..
- Medscape. 2020 Jun 25.
- Video series
- Free Full Text